Meeting
2011 ASCO Annual Meeting
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
Authors
K. Oliner
Amgen Inc., Thousand Oaks, CA
K. Oliner , M. Peeters , S. Siena , E. Van Cutsem , J. Huang , Y. Humblet , J. Van Laethem , T. Andre , J. S. Wiezorek , S. D. Patterson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00113763, NCT00113776
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3530)
Abstract #
3530
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.
First Author: Michael Boedigheimer
![PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. .](https://d201v5jt9ylckg.cloudfront.net/102/6682/61160/61160_poster_pv.jpg)
First Author: J. Maurel
Poster
2022 ASCO Annual Meeting
Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab).
First Author: Andreas Jay Kind
Poster
2020 Gastrointestinal Cancers Symposium
Clinical utility of targeted next generation sequencing (NGS) to predict response to neoadjuvant therapy (NT) in rectal cancer (RC).
First Author: Kristen Carroll